The evidence on peptides — delivered weekly. Subscribe free →

Orforglipron

moderate risk

Also: LY3502970 · Oral GLP-1 small molecule

Moderate Evidence Research Only

Orforglipron is a non-peptide, oral, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Not technically a peptide but included due to its positioning in the GLP-1 space. Phase III trials show ~14.7% weight loss — competitive with injectable semaglutide. Potential to democratize GLP-1 access via oral dosing.

Molecular Weight
N/A (small molecule)
Formula
Unknown (proprietary non-peptide)
Common Dosing
Phase III oral dosing: 3–36 mg/day
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Weight loss

Moderate Evidence 12 studies

Phase III ATTAIN-1: 14.7% body weight loss at 36 weeks — comparable to semaglutide without injection.

Mechanism of Action

Non-peptide small molecule binding to GLP-1 receptor extracellular domain at the same site as peptide GLP-1 agonists; full receptor agonism with oral bioavailability — solves the peptide delivery challenge.

Key Clinical Studies

Wharton et al. (Phase 2b) (2023)

Phase II RCT · n=272

PubMed →

Dose-dependent weight loss 9.4–14.7% at 26 weeks

The Oral Advantage

Solving the injection barrier for GLP-1 therapy could dramatically expand market access and patient adherence. Orforglipron’s non-peptide nature avoids the food absorption variability issue with oral semaglutide (Rybelsus requires strict fasting protocol). If Phase III confirms, it could reshape the GLP-1 market.

Not a peptide, but included because practitioners in this space need comparative context.

✦ Sponsored

Stop Guessing About Your Health. Start Optimizing It.

Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.

Learn More →
Nava Health

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Nausea
  • •Vomiting
  • •Diarrhea
  • •Constipation
  • •Hepatic enzyme elevation

Contraindications

  • •Pregnancy
  • •Severe hepatic impairment

Drug Interactions

  • •Insulin/sulfonylureas

Primary Uses

Weight lossType 2 diabetesOral GLP-1 agonism

Related Peptides

SemaglutideTirzepatideRetatrutideLiraglutide

Planning a protocol?

Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.

Stack Builder → Protocol Builder →

Weekly Briefing

Regulatory updates + new study breakdowns.

Related Articles

› The Complete GLP-1 Class Comparison: Semaglutide vs. Tirzepatide vs. Retatrutide vs. CagriSema

For Practitioners

Do you prescribe Orforglipron?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.